Nymox pharmaceutical corp (NYMX)
Balance Sheet / Quarterly
Sep'18Jun'18Mar'18Dec'17Dec'16Dec'15
ASSETS
Current assets
Cash

4,658

5,040

850

851

2,018

374

Accounts receivable

9

16

15

79

6

1

Other receivables

8

10

8

8

3

7

Security deposit

23

7

7

7

7

0

Prepaid expenses

15

35

42

1

1

1

Research credits receivable

-

-

-

-

0

271

Inventory

38

40

14

15

3

38

Total current assets

4,751

5,148

936

961

2,038

692

Non-current assets
Security deposit

17

17

17

17

-

-

Property and equipment

11

1

1

1

2

3

Other assets

-

-

-

-

17

17

Total assets

4,779

5,166

954

979

2,057

712

Liabilities and Stockholders Equity (Deficit)
Current liabilities
Accounts payable and accrued liabilities

849

1,615

1,998

2,230

1,368

2,251

Convertible notes

-

-

-

-

931

814

Total liabilities

849

1,615

1,998

2,230

2,299

3,060

Stockholders Equity (Deficit)
Share capital - unlimited authorized shares at no par value 62,259 and 56,378 shares outstanding at September 30, 2018 and December 31, 2017, respectively

121,684

116,310

110,060

108,196

92,125

84,954

Share capital subscription receivable

-868

-868

-718

-718

0

0

Additional paid-in capital

35,507

37,711

36,797

35,790

38,724

30,674

Accumulated deficit

-152,393

-149,602

-147,183

-144,519

-131,091

-117,981

Total Stockholders' equity (deficit)

3,930

3,551

-1,044

-1,251

-241

-2,353

Business activities and future operations

-

-

-

-

0

0

Commitments and contingencies

-

-

-

-

0

0

Subsequent events

-

-

-

-

0

0

Total liabilities and stockholders equity (deficit)

4,779

5,166

954

979

2,057

712